Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Research & Development (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Research & Development for 16 consecutive years, with $127000.0 as the latest value for Q4 2025.

  • Quarterly Research & Development fell 9.29% to $127000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $470000.0 through Dec 2025, down 10.82% year-over-year, with the annual reading at $469000.0 for FY2025, 10.84% down from the prior year.
  • Research & Development hit $127000.0 in Q4 2025 for Guided Therapeutics, down from $136000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $222000.0 in Q2 2024 to a low of $7000.0 in Q1 2023.
  • Historically, Research & Development has averaged $68550.0 across 5 years, with a median of $60000.0 in 2023.
  • Biggest YoY gain for Research & Development was 762.5% in 2023; the steepest drop was 66.67% in 2023.
  • Year by year, Research & Development stood at $17000.0 in 2021, then skyrocketed by 129.41% to $39000.0 in 2022, then skyrocketed by 120.51% to $86000.0 in 2023, then skyrocketed by 62.79% to $140000.0 in 2024, then decreased by 9.29% to $127000.0 in 2025.
  • Business Quant data shows Research & Development for GTHP at $127000.0 in Q4 2025, $136000.0 in Q3 2025, and $133000.0 in Q2 2025.